What should I do if I become resistant to pitobrutinib?

Pirtobrutinib is a highly selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor primarily used to treat relapsed or refractory B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Although Pitobrutinib has achieved remarkable efficacy in treatment, some patients may face resistance problems.

Resistance mechanisms that emerge during treatment with pitobrutinib in patients with chronic lymphocytic leukemia (CLL) treated with covalent BTK inhibitors.

This study evaluated the efficacy and safety of the noncovalent BTK inhibitor pitobrutinib in patients who had previously developed resistance to a covalent BTK inhibitor. One of the most common mutations leading to resistance to BTK inhibitors is the C481S mutation. Pitobrutinib has shown activity against this mutation, demonstrating efficacy in a setting where other BTK inhibitors may fail. However, despite this advantage of pitobrutinib, patients eventually develop resistance to it, caused by multiple mutations other than BTK itself.

The BRUIN study identified a series of mutations in patients who progressed on pitobrutinib. Acquired BTK mutations were detected in 44% of these patients. However, 24% of patients had non-BTK mutations and no identifiable mutations were observed in 32% of patients, suggesting the presence of other resistance mechanisms.

Several nonBTK mutations associated with pitotinib resistance were observed, including TP53, NOTCH1, PLCG2, and BCL2 mutations. These mutations may contribute to disease persistence by activating pathways that bypass BTK inhibition or by promoting cell survival that is independent of the BTK pathway.

Specifically, mutations in TP53 and NOTCH1 are known to contribute to aggressive disease phenotypes and treatment resistance in a variety of hematological malignancies, suggesting that pitotinib resistance in these patients may be associated with broader genomic instability.

This complex resistance profile demonstrates that although pitobrutinib isC481S and other BTK mutations offer an effective treatment option for patients, but durable responses remain challenging. The diversity of resistance mechanisms emphasizes the need for comprehensive genomic analysis to effectively tailor subsequent treatments. For patients whose disease progresses on pitobrutinib, combination therapies or alternative agents targeting non-BTK pathways may be needed to overcome resistance.

The results of the BRUIN study highlight the importance of understanding BTK-dependent and BTK-independent resistance mechanisms to optimize treatment strategies for patients with BTK-mutant malignancies who have progressed on pitotinib.

In summary, individualized and comprehensive treatment strategies are needed to address pitobrutinib resistance. Patients should choose an appropriate treatment plan under the guidance of a doctor, combined with their own illness and physical condition, and continue to monitor and evaluate the treatment effect. At the same time, paying attention to the latest progress in new drug research and development and clinical trials is also an important way to overcome drug resistance and improve treatment effects.

xa0

Reference: https://www.onclive.com/view/david-c-fisher-md-discusses-pirtobrutinib-resistance-mechanisms-that-may-develop-during-therapy-in-patients-with-cll